B[Ten departments: Expand the scale of the precision diagnosis industry] On September 18, ten departments including the Ministry of Industry and Information Technology issued the "Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry", which mentioned the expansion of the scale of the precision diagnosis industry. Focus on the development of high-throughput gene sequencing, microfluidics, highly sensitive biological detection and other technologies, promote the integration and upgrading of in vitro diagnosis, medical imaging, pathological diagnosis, molecular diagnosis, multi-omics detection and other fields, and accelerate the industrialization of innovative diagnostic products. Improve the quality control, clinical evaluation and standard system of precision diagnostic products. Promote qualified medical institutions to develop precision diagnosis centers, strengthen cooperation with relevant enterprises, promote the interconnection and sharing of diagnosis and treatment data, accelerate the in-depth integration of precision diagnosis technology with digital health and artificial intelligence, and improve the level of precision diagnosis of rare diseases, tumors, genetic diseases, etc. B[The fifth day of the 2026 State Talks: Negotiation on the price of commercially insured innovative drugs begins. Many pharmaceutical companies enter the market with nuclear drugs, CAR-T new drugs and other blockbuster drugs] September 9th, at about 8 o'clock today, the fifth day of negotiation and bidding for the 2026 National Basic Medical Insurance Drug List and the price negotiation for the commercially insured innovative drugs officially started. The reporter learned on the spot that today is the last day of this year's State Talks, and intensive price negotiations for the commercially insured innovative drugs will be carried out. The negotiation and bidding for the basic medical insurance list were completed yesterday morning. Representatives from AstraZeneca, Sanofi, Keji Pharmaceutical subsidiary Kaixing Life, Yuanda, Hengrun Dasheng, Precision Biotech and other companies entered the negotiation venue one after another. This year, a total of 62 drug generic names were applied for in the commercial insurance innovative drug catalog price negotiation, and 58 passed the formal review, of which 57 were outside the catalog and 1 was within the catalog. Rare diseases, tumors, and neurological diseases were still the main applicants, accounting for about 70% in total. Two new CAR-T drugs, Hengrun Dasheng's Ranicchiolense Injection and Precision Biotech's Pulgeolense Injection, tried to "break through" for the first time. (Reporters Lu Afeng and Yu Miao) B[The concept of innovative drugs rebounded with shock and Dezhan Health had 2 boards in 3 days] On September 7th, the concept of innovative drugs rebounded with shock and 2 boards in 3 days. Dezhan Health had 2 boards in 3 days. Haooubo rose by nearly 10%. Qianjin Pharmaceutical, Wanbang Pharmaceutical, Borui Pharmaceutical, Harbin Pharmaceutical Co., Ltd., etc. followed suit. In terms of news, the National Medical Insurance Administration made it clear at a press conference held by the State Council Information Office on September 4 that during the “15th Five-Year Plan” period, the medical insurance drug catalog will continue to be adjusted every year to include more innovative drugs in major disease fields such as tumors, chronic diseases, rare diseases, and children for reimbursement. At the same time, we will promote the national unification of the reimbursement catalog for medical services and consumables and narrow regional differences.
— All loaded —
